These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 25374314)
1. Preparing effective experimental data for pharmaceutical patent applications from US and Japanese perspectives. Altman D; Sweeney C; Yasui T Pharm Pat Anal; 2014 Sep; 3(5):469-73. PubMed ID: 25374314 [No Abstract] [Full Text] [Related]
2. Old drugs, new uses: solving a Hatch-Waxman patent predicament. McPhie DC Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929 [No Abstract] [Full Text] [Related]
3. The application of the patent laws to the drug approval process. Coggio BD; Cerrito FD Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669 [No Abstract] [Full Text] [Related]
4. Patent protection for medical technologies: why some and not others? Melzer D Lancet; 1998 Feb; 351(9101):518-9. PubMed ID: 9482467 [No Abstract] [Full Text] [Related]
5. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers. Soehnge H Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584 [No Abstract] [Full Text] [Related]
6. U.S. patent law. Case probes what's fair game in the search for new drugs. Kintisch E Science; 2005 Apr; 308(5719):174. PubMed ID: 15821048 [No Abstract] [Full Text] [Related]
7. A precarious balancing act--the role of the FDA as protector of public health and industry wealth. McCabe AR Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844 [No Abstract] [Full Text] [Related]
8. The ongoing regulation of generic drugs. Frank RG N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956 [No Abstract] [Full Text] [Related]
9. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity. Fernandez DS; Huie JT Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155 [No Abstract] [Full Text] [Related]
10. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses. Tang WL Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553 [TBL] [Abstract][Full Text] [Related]
11. Generics still unable to resolve ANDA patent issues by declaratory judgment, but is a supreme court resolution on the way? Eccleston LE Health Care Law Mon; 2006 Dec; ():3-5. PubMed ID: 17236678 [No Abstract] [Full Text] [Related]
12. Realizing two-tiered innovation policy through drug regulation. Ridgway WE Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807 [No Abstract] [Full Text] [Related]
13. Should the patent system for new medicines be abolished? DiMasi JA; Grabowski HG Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100 [No Abstract] [Full Text] [Related]
14. "Obvious to try": a proper patentability standard in the pharmaceutical arts? Trask AV Fordham Law Rev; 2008 Apr; 76(5):2625-68. PubMed ID: 18546581 [No Abstract] [Full Text] [Related]
15. The errors of error testing: potential liability issues for medication error testing of pharmaceutical trademarks under U.S. law. Thomas JA Food Drug Law J; 2004; 59(2):325-37. PubMed ID: 15298014 [No Abstract] [Full Text] [Related]
16. A cheat sheet to navigate the complex maze of exclusivities in the United States. Peng B; Tomas MC Pharm Pat Anal; 2014 Jul; 3(4):339-43. PubMed ID: 25291306 [No Abstract] [Full Text] [Related]
17. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma. Wang Z Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001 [No Abstract] [Full Text] [Related]
19. On access and accountability--two Supreme Court rulings on generic drugs. Boumil MM; Curfman GD N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990 [No Abstract] [Full Text] [Related]
20. Branded drug reformulation: the next brand vs. generic antitrust battleground. Amoresano GV Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032 [No Abstract] [Full Text] [Related] [Next] [New Search]